Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
FDA approves Eli Lilly's Zepbound for obesity and moderate-to-severe obstructive sleep apnea, marking the first drug treatment for OSA. Zepbound should be used with a reduced-calorie diet and increased physical activity. Approval may impact insurance coverage, giving Eli Lilly an edge over Novo Nordisk. Clinical trials showed nearly half of patients experienced disease resolution.
Highlighted Terms
Related News
FDA approves Eli Lilly's Zepbound for obesity and moderate-to-severe obstructive sleep apnea, marking the first drug treatment for OSA. Zepbound should be used with a reduced-calorie diet and increased physical activity. Approval may impact insurance coverage, giving Eli Lilly an edge over Novo Nordisk. Clinical trials showed nearly half of patients experienced disease resolution.